Celldex Therapeutics, Inc.
CLDX Nasdaq
SEC CIK 744218
Follow Celldex Therapeutics
Weekly email: filings, results
Revenue, last quarter
$0
Net income
−$75.6M
−12.7% vs same quarter last year
EPS, diluted
−$0.96
+5% vs same quarter last year
Operating cash flow
−$65M
−33.7% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $1.5M | −$258.8M |
| FY24 | $7M | −$157.9M |
| FY23 | $6.9M | −$141.4M |
| FY22 | $2.4M | −$112.3M |
| FY21 | $4.7M | −$70.5M |
| FY20 | $7.4M | −$59.8M |
| FY19 | $3.6M | −$50.9M |
| FY18 | $9.5M | −$151.2M |
| FY17 | $12.7M | −$93M |
| FY16 | $6.8M | −$128.5M |
| FY15 | $5.5M | −$127.2M |
| FY14 | $3.6M | −$118.1M |
| FY13 | $4.1M | −$81.6M |
| FY12 | $11.2M | −$59.1M |
| FY11 | $9.3M | −$44.8M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 87.1% | −18599.8% | −16748% |
| FY24 | 97.2% | −2778.9% | −2248.8% |
| FY23 | 95.6% | −2245.3% | −2054.8% |
| FY22 | 95.8% | −4889% | −4765.6% |
| FY21 | 97.8% | −1531.8% | −1516% |
| FY20 | 97.3% | −854.1% | −805.9% |
| FY19 | 97.2% | −1540.2% | −1424% |
| FY18 | 92.7% | −1640.1% | −1585.1% |
| FY17 | 94.5% | −953.7% | −730.1% |
| FY16 | 76.4% | −1958.7% | −1894% |
| FY15 | - | −2363.9% | −2321.1% |
| FY14 | - | −3414.1% | −3292.8% |
| FY13 | - | −1981.1% | −1983.7% |
| FY12 | - | −518.5% | −527.8% |
| FY11 | - | −468.4% | −483.5% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$213.7M |
| FY24 | −$159.7M |
| FY23 | −$109.1M |
| FY22 | −$105.6M |
| FY21 | −$62.2M |
| FY20 | −$42M |
| FY19 | −$47.1M |
| FY18 | −$76M |
| FY17 | −$101.7M |
| FY16 | −$115.8M |
| FY15 | −$103.8M |
| FY14 | −$103.5M |
| FY13 | −$71.9M |
| FY12 | −$50.1M |
| FY11 | −$36.2M |
- Celldex Therapeutics
- Healthcare median
Show the numbers
| Year | Celldex Therapeutics | Healthcare median |
|---|---|---|
| FY25 | −16748% | −30.6% |
| FY24 | −2248.8% | −47% |
| FY23 | −2054.8% | −58% |
| FY22 | −4765.6% | −80.4% |
| FY21 | −1516% | −71.9% |
| FY20 | −805.9% | −62.2% |
| FY19 | −1424% | −46.3% |
| FY18 | −1585.1% | −49.6% |
| FY17 | −730.1% | −45.9% |
| FY16 | −1894% | −36% |
| FY15 | −2321.1% | −38.4% |
| FY14 | −3292.8% | −35.5% |
| FY13 | −1983.7% | −37.1% |
| FY12 | −527.8% | −29.1% |
| FY11 | −483.5% | −27.9% |